Side-by-side comparison of AI visibility scores, market position, and capabilities
Conshohocken PA pharmaceutical distribution (NYSE: COR, formerly AmerisourceBergen) at $316B+ revenue; Retina Consultants of America acquisition $4.4B (Jan 2025) expanding into specialty physician care competing with McKesson.
Cencora, Inc. (formerly AmerisourceBergen, rebranded August 2023) is a Conshohocken, Pennsylvania-based pharmaceutical distribution and healthcare services company — publicly traded on the New York Stock Exchange (NYSE: COR) as an S&P 500 Health Care component, ranked #10 on the 2024 Fortune 500 and #24 on the Global Fortune 500 — distributing brand-name, generic, and specialty pharmaceuticals, over-the-counter products, and home healthcare supplies to 110,000+ points of care across 11 countries through 46,000+ employees and $316+ billion in annual revenue. Cencora operates as one of the "Big Three" pharmaceutical wholesalers in the United States alongside McKesson and Cardinal Health, collectively supplying approximately 90%+ of the US pharmaceutical supply chain. The company distributes from 26 US pharmaceutical distribution centers and 1,300+ locations across 50+ countries. In January 2025, Cencora completed the acquisition of approximately 85% interest in Retina Consultants of America (RCA) — a leading management services organization for retina specialists — for $4.4 billion, advancing its strategy to expand from pharmaceutical distribution into specialty physician-administered treatments and the high-growth specialty pharmaceutical services market. Founded through the 2001 merger of AmeriSource Health Corporation and Bergen Brunswig Corporation, with predecessor companies tracing to the 1970s, Cencora adopted its current name (meaning "center, core, heart" in multiple languages) in 2023 to signal the brand's evolution beyond commodity distribution.
AI quality assurance with insurance-backed warranties from Swiss Re and Greenlight Re; EU AI Act compliance assessments backed by YC and reinsurance partners for high-risk AI deployments.
Armilla AI is a third-party AI quality assurance and warranty company that evaluates AI models for organizations deploying AI in regulated or high-stakes contexts — assessing models against EU AI Act and NIST AI Risk Management Framework requirements for risks including bias, hallucination, robustness failures, and adversarial vulnerabilities, then providing performance guarantees backed by insurance coverage from reinsurers Swiss Re, Greenlight Re, and Chaucer. Founded in Toronto, Canada, Armilla raised $6.81 million total including a C$4.5 million seed round in February 2024 from Mistral Venture Partners, MS&AD Ventures, Y Combinator, and its reinsurance partners.\n\nArmilla's model is unique in the AI governance market — rather than just providing compliance reports, Armilla backs its assessments with insurance warranty products. An enterprise deploying a third-party AI model can purchase an Armilla warranty that pays out if the model performs differently than assessed (fails on bias, accuracy, or robustness metrics), transferring AI performance risk to insurance markets that can price and distribute it. This insurance mechanism creates financial accountability for AI quality claims that audit reports alone don't provide.\n\nIn 2025, Armilla competes in the AI governance, risk, and compliance market with Credo AI, Arthur AI, and AI audit firms for enterprise AI risk assessment and compliance tools. The EU AI Act, fully applicable by August 2025 for high-risk AI systems, is driving enterprise compliance urgency — companies deploying AI in hiring, credit scoring, healthcare, and other regulated contexts need third-party conformity assessments. Armilla's insurance-backed warranty differentiates its offering from pure advisory competitors. The reinsurer backing (Swiss Re, Greenlight Re, Chaucer) provides both capital credibility and distribution through insurance broker channels. The 2025 strategy focuses on growing EU AI Act compliance assessments and expanding the warranty product coverage to more AI deployment use cases.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.